Abstract
Many important clinical questions concerning primary Sjogren’s syndrome (pSS) remain, that can only be adequately addressed by prospective cohorts. Thus, a better knowledge of the clinical outcome, the course of disease activity and the risk factors of lymphoma requires the setting up of cohorts with biobanks. The homogeneous collection of clinical data, disease activity, patient-related outcome, and biological samples, including DNA, RNA and serum, is definitively mandatory to determine new biological prognostic factors and identify disease activity markers. Three large prospective cohorts have already started to enroll patients with pSS. This will be highly invaluable for scientists and clinicians to gain a better insight into the pathogenesis of pSS, as well as to identify prognostic markers and new therapeutic targets.
Keywords: Sjogren’s syndrome, prospective, cohort, disease activity, marker, clinical outcome, pathogenesis, therapeutic targets, clinical data, dryness symptoms, clinical disease, physical fatigue, prognostic factors, Sjogren’s International Collaborative Clinical Alliance (SICCA), clinical data.
Current Pharmaceutical Biotechnology
Title:Primary Sjogren’s Syndrome: Time for Prospective Cohorts
Volume: 13 Issue: 10
Author(s): Jacques-Eric Gottenberg and Xavier Mariette
Affiliation:
Keywords: Sjogren’s syndrome, prospective, cohort, disease activity, marker, clinical outcome, pathogenesis, therapeutic targets, clinical data, dryness symptoms, clinical disease, physical fatigue, prognostic factors, Sjogren’s International Collaborative Clinical Alliance (SICCA), clinical data.
Abstract: Many important clinical questions concerning primary Sjogren’s syndrome (pSS) remain, that can only be adequately addressed by prospective cohorts. Thus, a better knowledge of the clinical outcome, the course of disease activity and the risk factors of lymphoma requires the setting up of cohorts with biobanks. The homogeneous collection of clinical data, disease activity, patient-related outcome, and biological samples, including DNA, RNA and serum, is definitively mandatory to determine new biological prognostic factors and identify disease activity markers. Three large prospective cohorts have already started to enroll patients with pSS. This will be highly invaluable for scientists and clinicians to gain a better insight into the pathogenesis of pSS, as well as to identify prognostic markers and new therapeutic targets.
Export Options
About this article
Cite this article as:
Gottenberg Jacques-Eric and Mariette Xavier, Primary Sjogren’s Syndrome: Time for Prospective Cohorts, Current Pharmaceutical Biotechnology 2012; 13 (10) . https://dx.doi.org/10.2174/138920112802273128
DOI https://dx.doi.org/10.2174/138920112802273128 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
SHIP2: An Emerging Target for the Treatment of Type 2 Diabetes Mellitus
Current Drug Targets - Immune, Endocrine & Metabolic Disorders The Holy Grail of Polymer Therapeutics for Cancer Therapy: An Overview on the Pharmacokinetics and Bio Distribution
Current Drug Metabolism Targets for Medical Therapy to Limit Abdominal Aortic Aneurysm Progression
Current Drug Targets Managing Nutrition for Cancer Patients during COVID-19: Review
Current Nutrition & Food Science Neuro-Immune-Endocrine Mechanisms During Septic Shock: Role For Nitric Oxide in Vasopressin and Oxytocin Release
Endocrine, Metabolic & Immune Disorders - Drug Targets Nanoparticles: A Promising Therapeutic Approach in Atherosclerosis
Current Drug Delivery HIV-1 Prophylactic Vaccine Trials in Thailand
Current HIV Research Photodynamic Therapy For Non-Melanoma Skin Cancers
Current Cancer Therapy Reviews Meet Our Editorial Board Member:
Current Protein & Peptide Science Ketamine: New Indications for an Old Drug
Current Drug Targets Genetic Variability of Matrix Metalloproteinase Genes in Cardiovascular Disease
Current Topics in Medicinal Chemistry Ulnar Artery Thrombosis Due to Hypothenar Hammer Syndrome
Recent Patents on Cardiovascular Drug Discovery High-Speed Screening and Quantitative SAR Analysis of Human ABC Transporter ABCG2 for Molecular Modeling of Anticancer Drugs to Circumvent Multidrug Resistance
Mini-Reviews in Medicinal Chemistry Obesity and Adipose Tissue-derived Cytokines in the Pathogenesis of Multiple Sclerosis
Endocrine, Metabolic & Immune Disorders - Drug Targets Animal Models of Depressive Illness: The Importance of Chronic Drug Treatment
Current Pharmaceutical Design Fragment-Based Drug Design: Computational and Experimental State of the Art
Combinatorial Chemistry & High Throughput Screening Implication of Possible Therapies Targeted for the Tachykinergic System with the Biology of Neurokinin Receptors and Emerging Related Proteins
Recent Patents on CNS Drug Discovery (Discontinued) Drug-Induced Aseptic Meningitis
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Sirolimus Eluting Stent: A New Era in Interventional Cardiology?
Current Pharmaceutical Design HCV-Related Transformation and New Therapeutic Strategies: An Update
Current Cancer Therapy Reviews